Residency · Residency · Chronic Pain Management

Opioid Pharmacology: Receptors, Pharmacokinetics, and Pharmacodynamics

Introduction

A thorough understanding of opioid pharmacology is prerequisite to safe and effective prescribing in chronic pain management. This lecture covers the opioid receptor system, endogenous opioid peptides, the pharmacokinetics of commonly used opioids including critical concepts in metabolism, and the principles of equianalgesic dosing that underpin safe opioid rotation.

Opioid Receptor Physiology

Mu (MOP) Receptors

The mu receptor is the primary mediator of opioid analgesia. It is located in the periaqueductal gray, rostral ventromedial medulla, spinal dorsal horn, and peripheral nociceptors. Two subtypes are clinically relevant: mu-1, which mediates supraspinal analgesia and euphoria, and mu-2, which mediates respiratory depression, gastrointestinal dysmotility, physical dependence, and miosis. All clinically used opioid analgesics have significant mu receptor activity.

The mu receptor is a G-protein coupled receptor (Gi/Go). When activated, it decreases cyclic AMP production, increases potassium conductance (hyperpolarizing the neuron), decreases calcium conductance (reducing neurotransmitter release), and activates descending inhibitory pain pathways. These intracellular effects collectively suppress nociceptive transmission at multiple levels of the pain pathway.

Kappa (KOP) Receptors

Kappa receptors are located in the spinal cord, hypothalamus, and limbic structures. They mediate spinal analgesia, sedation, and — importantly — dysphoria. Kappa activation also produces diuresis through inhibition of antidiuretic hormone. The dysphoria and psychotomimetic effects associated with kappa agonism limit the clinical utility of pure kappa agonists. Butorphanol and pentazocine have significant kappa agonist activity, which accounts for their characteristic side effect profiles. Emerging research on kappa antagonists for mood disorders and addiction represents a promising area of investigation.

Delta (DOP) Receptors

Delta receptors are widely distributed in the brain (cortex, striatum, olfactory bulb) and spinal cord. They modulate mu-receptor activity and contribute to emotional and reward processing. They may mediate anxiolytic and antidepressant-like effects of endogenous opioids. Compared to mu receptors, delta receptors are less involved in respiratory depression. Delta-selective agonists are under investigation but none are currently available for clinical use.

Nociceptin/Orphanin FQ (NOP) Receptor

The NOP receptor is the fourth member of the opioid receptor family but does not bind classical opioids. Its endogenous ligand is nociceptin/orphanin FQ. It plays a complex role in pain modulation that can be either pronociceptive or antinociceptive depending on the anatomical site of action, making it an emerging therapeutic target for both pain and addiction.

<image>Comprehensive diagram of the three classical opioid receptor types (mu, kappa, delta) embedded in a neuronal cell membrane, showing G-protein coupling, intracellular signaling cascades for each receptor including cAMP reduction, potassium channel opening, and calcium channel closure, with tables alongside each receptor listing the clinical effects of activation (analgesia, euphoria/dysphoria, respiratory depression, GI effects, miosis) and the endogenous ligands that preferentially bind each receptor type</image>

Endogenous Opioid Systems

The body produces its own opioid peptides organized into three major families. Beta-endorphin, derived from pro-opiomelanocortin (POMC), has preferential mu receptor affinity and is released from the hypothalamus and pituitary. The enkephalins (met-enkephalin and leu-enkephalin), derived from proenkephalin, preferentially bind delta receptors and are widely distributed in the CNS and adrenal medulla. The dynorphins, derived from prodynorphin, have preferential kappa receptor affinity and are found in the spinal cord and hypothalamus.

These endogenous opioid systems serve multiple functions beyond analgesia: they mediate stress-induced analgesia, modulate reward and motivation circuits, regulate neuroendocrine function (cortisol and gonadotropins), and participate in immune system modulation. Chronic pain states may involve dysregulation of endogenous opioid tone, contributing to pain amplification — a concept that helps explain why some patients with chronic pain seem to have a fundamentally altered relationship with pain processing.

Bioavailability of Oral Opioids

Oral bioavailability varies widely among opioids due to differences in first-pass hepatic metabolism. Morphine has a bioavailability of only 20-40%, creating a large oral-to-parenteral dose ratio (3:1). Oxycodone achieves 60-87%, allowing more predictable oral dosing. Hydromorphone sits at 24-50% with a significant first-pass effect. Hydrocodone has good oral bioavailability at approximately 70-80%. Methadone is highly predictable at 70-90%. Fentanyl has less than 10% oral bioavailability (but 50-65% transmucosally), making it unsuitable for standard oral administration. Tapentadol has moderate bioavailability at 32%.

These differences are affected by hepatic blood flow, genetic polymorphisms in metabolizing enzymes, food intake, and concurrent medications — all factors that contribute to interpatient variability in opioid response.

Metabolism: CYP2D6 Polymorphisms

CYP2D6-Dependent Opioids

Several commonly used opioids depend on CYP2D6 for their analgesic activity. Codeine is a prodrug with essentially no analgesic activity until CYP2D6 converts it to morphine. Tramadol is similarly converted to O-desmethyltramadol, an active metabolite with 200-fold higher mu receptor affinity than the parent compound. Hydrocodone is converted to hydromorphone via CYP2D6, contributing to its analgesic effect. Oxycodone is converted to oxymorphone by CYP2D6, though this is a minor contribution to overall analgesia since oxycodone is primarily metabolized by CYP3A4.

CYP2D6 Phenotypes

Genetic variation in CYP2D6 has direct clinical consequences. Poor metabolizers (5-10% of Caucasians) lack functional CYP2D6, rendering codeine and tramadol ineffective. Intermediate metabolizers have reduced but present activity, producing decreased and variable drug response. Extensive metabolizers — the majority of the population — have normal metabolism and standard drug response. Ultra-rapid metabolizers (1-10% of the population, with higher prevalence in North African and Middle Eastern populations) convert codeine to morphine so rapidly that toxicity, respiratory depression, and death can result. This led to the FDA black box warning for codeine in pediatric patients following deaths in ultra-rapid metabolizer children post-tonsillectomy.

CYP3A4-Dependent Metabolism

Fentanyl, methadone, and oxycodone (via its primary pathway) are metabolized by CYP3A4. Drug interactions with CYP3A4 inhibitors (ketoconazole, clarithromycin, grapefruit juice) can dramatically increase opioid levels, while inducers (rifampin, carbamazepine, phenytoin) can reduce opioid efficacy. These interactions are clinically significant and must be actively monitored.

<image>Metabolic pathway diagram for the major opioids showing CYP2D6 and CYP3A4 pathways, with codeine converting to morphine via CYP2D6, tramadol to O-desmethyltramadol, hydrocodone to hydromorphone, and oxycodone via both CYP2D6 (to oxymorphone) and CYP3A4 (to noroxycodone), with color-coded arrows indicating active versus inactive metabolites, and a population distribution chart showing the frequency of poor, intermediate, extensive, and ultra-rapid CYP2D6 metabolizer phenotypes across different ethnic populations</image>

Equianalgesic Dosing

Principles

Equianalgesic tables provide approximate dose ratios for converting between opioids. The standard reference point is morphine 30 mg oral, which equals morphine 10 mg intravenously. A critical nuance is that these ratios are derived from single-dose studies in opioid-naive patients and may not apply directly to chronic dosing situations.

Standard Equianalgesic Table (Oral Doses)

The key conversions are as follows: morphine 30 mg oral (10 mg IV), oxycodone 20 mg oral, hydromorphone 6 mg oral (1.5 mg IV), hydrocodone 30 mg oral, oxymorphone 10 mg oral (1 mg IV), and fentanyl 100 mcg IV. Methadone has a variable ratio that changes with dose and is discussed separately below.

Opioid Rotation Principles

When rotating opioids, the first step is to calculate the total daily dose of the current opioid in oral morphine equivalents (OME). A dose reduction of 25-50% is then applied to account for incomplete cross-tolerance — the phenomenon in which tolerance to one opioid does not fully transfer to another. Greater dose reductions of 50% are warranted for high-dose opioid therapy (above 100 OME per day), elderly patients, patients with renal or hepatic impairment, and rotation to methadone.

Methadone Conversion Complexity

Methadone conversion is the most dangerous opioid rotation because of its non-linear equianalgesic ratio. The morphine-to-methadone ratio increases as the morphine dose increases: at less than 90 OME per day, the ratio is approximately 4:1; at 90-300 OME per day, it rises to 8:1; and above 300 OME per day, the ratio is 12:1 or higher. Methadone's long and highly variable half-life (8-59 hours) creates a risk of delayed-onset respiratory depression that may not manifest until days after a dose change. Methadone rotation should only be performed by experienced clinicians with close monitoring over a minimum of 5-7 days.

<image>Equianalgesic dosing reference card showing a visual conversion wheel or ladder diagram with morphine at the center, radiating outward to oxycodone, hydromorphone, hydrocodone, fentanyl patch, and methadone, with conversion ratios on each connecting line, a highlighted warning zone for methadone's non-linear conversion ratio shown as a dose-dependent sliding scale, and a checklist of dose reduction factors to apply during opioid rotation</image>

Pharmacodynamic Considerations

Several pharmacodynamic phenomena are essential to understand in chronic opioid therapy. Tolerance is a diminished response to a fixed opioid dose over time; it develops at different rates for different effects, with tolerance to sedation and nausea developing faster than tolerance to constipation or respiratory depression. Physical dependence is a neuroadaptation that produces a withdrawal syndrome upon abrupt cessation or antagonist administration — it is distinct from addiction and is an expected physiological consequence of chronic opioid exposure. Opioid-induced hyperalgesia (OIH) is a paradoxical increase in pain sensitivity caused by chronic opioid exposure, mediated by NMDA receptor activation and glial cell activation. Ceiling effects are seen with partial agonists like buprenorphine, which exhibit dose-response plateaus; pure mu agonists do not have analgesic ceilings, but their toxicity increases proportionally with dose.

Clinical Pearls

CYP2D6 genotyping should be considered before prescribing codeine or tramadol, particularly in pediatric patients and populations with high ultra-rapid metabolizer prevalence. Methadone conversion is the most dangerous opioid rotation due to its variable half-life and non-linear equianalgesic ratios — always reduce dose more conservatively than with other rotations. The distinction between tolerance, physical dependence, and addiction is fundamental: physical dependence is an expected physiological adaptation, not evidence of addiction. Fentanyl transdermal patches should not be prescribed to opioid-naive patients, as the FDA black box warning reflects deaths from inappropriate initial dosing. Always apply a 25-50% dose reduction when rotating between opioids to account for incomplete cross-tolerance. Opioid-induced hyperalgesia should be suspected when pain paradoxically worsens with dose escalation — treatment involves dose reduction or opioid rotation, not further escalation.

References

1. Pasternak GW, Pan YX. Mu opioids and their receptors: evolution of a concept. Pharmacol Rev. 2013;65(4):1257-1317.
2. Smith HS. Opioid metabolism. Mayo Clin Proc. 2009;84(7):613-624.
3. Crews KR, Gaedigk A, Dunnenberger HM, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther. 2014;95(4):376-382.
4. Webster LR, Fine PG. Review and critique of opioid rotation practices and associated risks of toxicity. Pain Med. 2012;13(4):562-570.

Read this lecture as Markdown